Xu Li-Xin, Cao Yong-Bin, Liu Zhou-Yang, Wu Ya-Mei, Wang Zhi-Hong, Yan Bei, DA Wan-Ming, Wu Xiao-Xiong
Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
Department of Hematology, Chinese PLA General Hospital, Beijing 100048, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Dec;21(6):1522-5. doi: 10.7534/j.issn.1009-2137.2013.06.029.
This study was purposed to investigate the safety and effectivity of haploidentical stem cell transplantation for chronic aplastic anemia (CAA) by using two kind of third part cells: umbilical cord derived mesenchymal stem cells (hUC-MSC) and haploidentical umbilical cord blood cells. The patient is a girl of 12 year old with CAA for 11 years. The donor was her mother. Graft come from haploidentical hematopoietic bone marrow and peripheral blood mobilized with granulocyte colony-stimulating factor (G-CSF). The human umbilical cord derived mesenchymal stem cells and the haploidentical umbilical cord blood cells were transferred as third pard of cell. The graft-versus-host disease (GVHD) was prevented with CsA, MTX, ATG, CD25 and mycophenolate mofetil. The results indicated that the infused numbers of MNC and CD34(+) cells of donor were 7.92×10(8)/kg and 3.78×10(6)/kg, respectively. The numbers of neutrophils and platelets were over 0.5×10(9)/L and 20×10(9)/L on days 12 and 14, respectively. On day 35 the chimeras accounted for 94%. No serious complications appeared up to now. In conclusion, the preliminary results suggest that transplantation of haploidentical hematopoietic stem cells combined with two kind of third part cells is safe and satisfactory.
脐带间充质干细胞（hUC-MSC）和单倍体相合脐带血细胞，来研究单倍体相合干细胞移植治疗慢性再生障碍性贫血（CAA）的安全性和有效性。患者为一名12岁女孩，患CAA 11年。供者为其母亲。移植物来自单倍体相合造血骨髓和经粒细胞集落刺激因子（G-CSF）动员的外周血。将人脐带间充质干细胞和单倍体相合脐带血细胞作为第三方细胞进行输注。采用环孢素A（CsA）、甲氨蝶呤（MTX）、抗胸腺细胞球蛋白（ATG）、CD25和霉酚酸酯预防移植物抗宿主病（GVHD）。结果显示，供者单个核细胞（MNC）和CD34(+)细胞的输入数量分别为7.92×10(8)/kg和3.78×10(6)/kg。中性粒细胞和血小板数量分别在第12天和第14天超过0.5×10(9)/L和20×10(9)/L。在第35天，嵌合体占94%。截至目前未出现严重并发症。总之，初步结果表明，单倍体相合造血干细胞联合两种第三方细胞移植是安全且令人满意的。
